Want to see LPCN full AI Analyst Report?
LPCN Stock Chart & Stats
$2.15
$0.06(2.88%)
At close: 4:00 PM EDT
$2.15
$0.06(2.88%)
Day’s Range― - ―
52-Week Range$1.40 - $12.37
Previous Close$2.1
Volume29.43K
Average Volume (3M)3.75M
Market Cap
$12.61M
Enterprise Value-$2.23M
Total Cash (Recent Filing)$23.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 11, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding8,244,253
10 Day Avg. Volume11,167,962
30 Day Avg. Volume3,746,570
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-1.42
Enterprise Value/Gross Profit-1.45
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$5.00Price Target Upside132.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$631.25K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt reduces interest obligations, refinancing exposure, and balance-sheet pressure while the company advances its pipeline. This provides greater financial flexibility than a leveraged development-stage peer, although losses still require careful capital allocation and funding discipline.
Canadian TLANDO Approval And Commercialization PathRegulatory approval converts TLANDO from a development asset into a product with a defined commercialization opportunity in Canada. Partner-led launch execution can broaden Lipocine’s geographic reach and create a potential recurring revenue stream beyond development-stage financing.
Oral-delivery Platform And Late-stage PipelineA Phase 3 program gives Lipocine a potentially meaningful second value driver beyond testosterone replacement, while the oral, at-home format targets convenience in an important treatment area. Successful execution could support regulatory filing and partnership opportunities.
Bears Say
Declining Revenue And Deep LossesShrinking revenue combined with a substantial net loss indicates that the company has not yet established a predictable earnings base. Continued unprofitability can constrain reinvestment, increase dependence on external capital, and make future operating performance difficult to forecast.
Persistent Cash BurnNegative operating and free cash flow show that current activities consume rather than generate cash. If this pattern persists while products and pipeline programs require funding, Lipocine may need additional financing, potentially limiting strategic flexibility or diluting existing holders.
Clinical Execution Risk In BLOOMThe need to address mixed prior results and data anomalies makes the new Phase 3 study an important execution hurdle. Even with centralized rating and stronger site controls, another inconclusive result could delay an NDA, raise development costs, and weaken pipeline value.
Lipocine News
LPCN FAQ
What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $1.40 and its highest was $12.37 in the past 12 months.
What is Lipocine’s market cap?
Lipocine’s market cap is $12.61M.
When is Lipocine’s upcoming earnings report date?
Lipocine’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Lipocine’s earnings last quarter?
Lipocine released its earnings results on Aug 04, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.08.
Is Lipocine overvalued?
According to Wall Street analysts Lipocine’s price is currently Undervalued.
Does Lipocine pay dividends?
Lipocine does not currently pay dividends.
What is Lipocine’s EPS estimate?
Lipocine’s EPS estimate is -0.36.
How many shares outstanding does Lipocine have?
Lipocine has 8,244,253 shares outstanding.
What happened to Lipocine’s price movement after its last earnings report?
Lipocine reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went up 0.948%.
Which hedge fund is a major shareholder of Lipocine?
Currently, no hedge funds are holding shares in LPCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipocine
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
LPCN Stock 12 Month Forecast
Average Price Target
$5.00
▲(132.56% Upside)
Technical Analysis
Ownership Overview
5.07% Insiders
3.10% Mutual Funds
20.74% Other Institutional Investors
68.05% Public Companies and
Individual Investors